Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2584 - Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective - A real-life analysis.


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site



Frederic Peyrade


Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289


F. Peyrade1, M. Kogay1, J. Viotti2, P. Combemale3, C. Dutriaux4, N. Dupin5, C. Robert6, L. Mortier7, A. Duval-Modeste8, S. Dalle9, J. De Quatrebarbes10, A. Stefan11, F. Brunet-Possenti12, A. Picard13, G. Poissonnet14, H. Montaudié15

Author affiliations

  • 1 Medical Oncology, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 2 Unit Of Epidemiology And Biostatistics (ueb), Centre Antoine Lacassagne, 06189 - Nice/FR
  • 3 Dermatology, Venereology, Centre Léon Bérard, 690008 - Lyon/FR
  • 4 Dermatology Department, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 5 Dermatology Department, APHP, Hôpital Cochin, 75014 - Paris/FR
  • 6 Department Of Dermatology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 7 Onco Dermatology, Hopital Claude Huriez, 59037 - Lille/FR
  • 8 Dermatology Department, Institute for Research and Innovation in Biomedicine, INSERM 1234, Rouen University Hospital, University of Normandie, 76000 - Rouen/FR
  • 9 Dermatology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 10 Dermatology, CH Annecy Genevois, 74370 - Annecy/FR
  • 11 Dermatology, CHU de Caen, 14033 - Caen/FR
  • 12 Dermatology Venerology, AP-HP BICHAT, 750018 - Paris/FR
  • 13 Dermatology, Centre Hospitalier Universitaire, Hôpital Archet, Nice, 06000 - Nice/FR
  • 14 Head And Neck, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 15 Department Of Dermatology, Centre Hospitalier Universitaire de Nice, Nice/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2584


Approximately 20-30% of non-melanoma skin cancers are squamous cell carcinomas of the skin (SCCS). SCCS incidence is increasing and they often occur in elderly or immunosuppressed patients (pts). SCCS can progress to stages impossible to treat by surgical excision or radiotherapy. Cisplatin-based combinations show efficacy but are too toxic for elderly pts. Cetuximab (Ce) demonstrates 69% disease control rate (DCR) at 6 weeks but in few, highly selected pts. This study aims to evaluate the efficacy of Ce in non-selected pts with SCCS.


This retrospective study included pts with relapsing unresectable or metastatic SCCS treated with Ce monotherapy (weekly loading dose 400 and 250 mg/m²). The primary objective was DCR at 6 weeks. 60 pts (38 male) with local relapses of metastatic CSCC (100%), were treated between 30/05/2007 and 07/04/2017 in 13 centers. Median age was 83.1 yrs (min 47.4, max 96.1 yrs). Two-thirds of pts had one or two comorbidities, including 13% (n = 8) with immune disorder. 54% had local relapse. Main metastatic locations were nodes (n = 15), lung (n = 8) and skin (n = 5). 90% were chemotherapy-naïve, 57% had previous radiotherapy, and all were primarily resected. Mean time between previous treatment and Ce was 20.1 months (min 0, max 300). Mean Ce injection number was 24.8 (min 4, max 60).


Complete response, partial response, stabilization (S) and progression were 7%, 48%, 32% and 13%, respectively, at 6 weeks and 2%, 42%, 29% and 27% at 3 months. 90% of pts experienced at least a disease S as best overall response. Ce was discontinued in 1 patient after first injection due to grade III infusion-related toxicity. All other grade III toxicities were cutaneous (n = 8) with 5 discontinuations. No toxic deaths were reported. Median follow-up, progression-free survival and overall survival were 11.7 months [95% CI: 9.6-30.1], 9.7 months [95% CI: 4.8-43.4] and 17.5 months [95% CI: 9.4-43.1] respectively.


Cetuximab is a safe and efficient treatment for patients, even very old, with SCCS. The toxicity profile of Ce compares very favorably with cisplatine-based protocols. These results indicate that Ce is a promising platform to test new combinations.

Clinical trial identification

Legal entity responsible for the study

Centre Antoine Lacassagne.


Merck KGaA.

Editorial Acknowledgement


F. Peyrade: Board member: Merck KGaA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.